|
Medical Advocates Darunavir(Prezista/TMC-114) |
 Darunavir Main Page |
 Main
New/Newsworthy
|
Home
Page |
Last
Update:
July 31, 2011
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Study of the immunomodulant effect of darunavir and maraviroc on apoptosis of PBMC I. Sauzullo, F. Mengoni, A. Ermocida, et al Poster Abstract I. Castillo Romera, N. Trovato López, S. Plata Paniagua, et al Poster Abstract Children's Clinical Centre of Excellence (COE) and decentralized ART sites in Botswana M. Tolle, A. Gomila, H. Jibril, et al Poster Abstract
K Chokephaibulkit, W Prasitsuebsai, O Wittawatmongkol, et al PDF Poster 
Abstract
with High Serum Triglycerides D Skiest, C Cohen, H Khanlou, et al PDF Poster
Abstract
HIV-infected Individuals A Jackson, D Back, S Khoo, et al PDF Poster
Abstract
POSTER B Taiwo, S Zheng, S Gallien, et al PDF Poster
Abstract
A Fun, D de Jong, M Nijhuis PDF Poster
Abstract
M Boffito, A Jackson, A Amara PDF Poster
Abstract
B Best, S Letendre, D Croteau, et al PDF Poster
Abstract
L Larrouy S Lambert-Niclot C Charpentier, et al Abstract Healthy Male Volunteers after Single and Multiple Dosing K Brown, K Patterson, S Jennings, et al Abstract
protease inhibitors on LIpids and other marKers): comparison of the metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir over 12 weeks J. Aberg, T. Overton, S. Gupta, et al PDF Poster
Abstract
Drug-resistant genotyping to guide selection of etravirine, darunavir and raltegravir in salvage therapy for multi-drug-resistant cases improves outcomes N. Miyazaki1, S. Matsushita, T. Fujii, et al PDF Poster
Abstract
clinical practice I. Castillo Romera, A. Ais Larisgoitia, V. Escudero Vilaplana, et al PDF Poster Abstract ART including darunavir/ritonavir G. Morsica, G. Bianchi, S. Bagaglio, et al Abstract The MONET trial 96 week analysis: darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for patients with HIV RNA < 50 copies/mL at baseline A. Rieger, D. Banhegyi, W. Schmidt, et al Abstract M.A. von Wichmann, M. Saenz-Cuesta, K. Aguirrebengoa, et al Abstract at week 48 in treatment-experienced, HIV-1-infected patients with no DRV resistance-associated mutations (RAMs) in the ODIN study J. Arribas, E. Arathoon, C.R. Gonsalez, et al Abstract lipid-lowering effect in healthy volunteers C. Fichtenbaum, D. Samineni, E. Moore, et al Abstract Etravirina-ETR, Raltegravir-RTG and Maraviroc-MVC) in the last four years (2006-2009) H. Azkune Galparsoro, J.A. Iribarren Loyarte, M.J. Aramburu Bengoechea Abstract darunavir/ritonavir (DRV/r) in treatment-experienced, HIV-1-infected patients with no DRV resistance-associated mutations (RAMs): ODIN 48-week data C. Workman, P. Benson, J. Valdez Madruga, et al Abstract ARV combinations in Mexico E. Vidal-Laurencio, L. Cabrera-Ruiz, A. Flores-Gaxiola, et al Abstract second-line protease inhibitors in South India S. Saravanan, M. Vidya, R. Kantor, et al Abstract patients in the ODIN trial P. Cahn, S. Hodder, P. Mootsikapun, et al Abstract
with CDRV/r Monotherapy vs 2 NRTI + DRV/r in the MONOI–ANRS 136 Randomized Trial: Results at 48 Weeks M-A Valantin, P Flandre, S Kolta, et al PDF Poster
Abstract
Resistant HIV-1 Variants Y Koh, M Aoki, M Amano, et al PDF Poster
Abstract
Darunavir Concentrations in Seminal Plasma in Patients Receiving Darunavir/Ritonavir Monotherapy: A MONOI-ANRS 136 Substudy S L-Niclot, C Duvivier, M Algarte-Genin, et al PDF Poster
Abstract
Children in the UK K Boyd, S Walker, D Dunn, et al PDF Poster
AbstractPOSTER Darunavir Concentrations Exceed the Protein-corrected EC50 for Wild Type HIV in the Semen of HIV-1+ Men S Taylor, A Jayasuriya, N Dufty, et al PDF Poster
Abstract
and Reverse Transcriptase Inhibitors in Heavily Pre-treated Subjects Infected with Multidrug Resistant HIV-1 F Codoñer, C Pou, A Thielen, et al PDF Poster
Abstract
B Roquebert, C Colin, A-M Taburet, et al PDF Poster
Abstract
|
- POSTER
ARTEMIS: lipid tolerability and safety of darunavir and lopinavir in antiretroviral-naïve patients
E Arathoon, E Baraldi, PL Lim, et al
PDF Poster 
- POSTER
ARTEMIS: Week 48 safety and efficacy of darunavir/r by gender, age and race
J Andrade-Villanueva, G Herrera, P Chiliade, et al
PDF Poster - POSTER
Comparable in-vitro susceptibility and virologic outcome to darunavir in patients infected
with subtype B and subtype non-B HIV isolates participating in the ARTEMIS Phase III trial
I Dierynck, S De Meyer, E Lathouwers, et al
PDF Poster - POSTER
Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir
and carbamazepine
VJ Sekar, F Tomaka, L Lavreys, et al
PDF Poster - POSTER
Dose selection and pharmacokinetics-pharmacodynamics of darunavir coadministered with low-dose ritonavir
in the DELPHI (TMC114-C212) trial in treatment-experienced, HIV-1-infected children and adolescents
V Sekar, T Van de Casteele, B Van Baelen, et al
PDF Poster - POWERPOINT POSTER
Effects of nucleoside analogues versus ritonavir boosted protease inhibitors on lipid levels – analysis of 12 clinical
trials in 4231 antiretroviral naïve patients
A Hill, B Gazzard
Poster -
Prevalence of major protease inhibitors (PIs) mutations for darunavir and
tipranavir resistance in samples of
experienced HIV patients from Buenos Aires
Abstract -
Resistance to LPV, TPV and DRV according to three different algorithms in
samples from highly
antiretroviral-therapy-
experienced-patients in Mexico City
Abstract -
Higher darunavir plasma levels and genotipic inhibitory quotient in patients
with rapid virological response
Abstract -
Pharmacokinetic interaction between darunavir in combination with low-dose
ritonavir (DRV/r) and
carbamazepine (CBZ)
Abstract -
Darunavir resistance related mutations in Mexican patients
Abstract -
The use of darunavir/ritonavir as intensification in low viremic HIV-infected
patients treated with boosted protease
inhibitor containing regimens
Abstract -
Combination antiretroviral treatment (CART) with darunavir/ritonavir (DRV/r) and
raltegravir (RAL) in patients with
multidrug resistant (MDR) HIV-1 infection in a community-based setting through an expanded access protocol
(EAP)
Abstract -
Combined darunavir (DRV) and etravirine (TMC125; ETR) resistance analysis of the
pooled DUET trials:
when can we spare the other new classes?
Abstract -
Comparable virologic response and in vitro susceptibility to darunavir in
patients infected with subtype B
and non-subtype B HIV isolates participating in the ARTEMIS Phase III Trial
